Pharmacology & Therapeutics

Article	Citations
Characteristics of anticancer activity of CBP/p300 inhibitors – Features of their classes, intracellular targets and future perspectives of their application in cancer treatment	939
SIRT3: A potential therapeutic target for liver fibrosis	340
Editorial Board	312
Epigenetic determinants and non-myocardial signaling pathways contributing to heart growth and regeneration	232
Berberine prevents NAFLD and HCC by modulating metabolic disorders	207
Is depression the missing link between inflammatory mediators and cancer?	197
Immunotherapy in melanoma: Can we predict response to treatment with circulating biomarkers?	194
TAS-102: A resurrected novel Fluoropyrimidine with expanding role in the treatment of gastrointestinal malignancies	162
Biased agonism in drug discovery: Is there a future for biased 5-HT1A receptor agonists in the treatment of neuropsychiatric diseases?	160
Novel pharmacological strategies to treat cognitive dysfunction in chronic obstructive pulmonary disease	157
Unraveling diverse roles of noncoding RNAs in various human papillomavirus negative cancers	136
Immune-related adverse events of cancer immunotherapies targeting kinases	133
Measuring brain docosahexaenoic acid turnover as a marker of metabolic consumption	126
The role of lidocaine in cancer progression and patient survival	117
Inter and intra-tumoral heterogeneity as a platform for personalized therapies in medulloblastoma	115
Anticancer drug delivery by focused ultrasound-mediated blood-brain/tumor barrier disruption for glioma therapy: From benchside to bedside	114
Prognostic and predictive molecular biomarkers in advanced colorectal cancer	113
Bioactive lipid regulation of platelet function, hemostasis, and thrombosis	112
Pharmacological interventions for intraplaque neovascularization in atherosclerosis	104
Mechanisms of skeletal muscle-tendon development and regeneration/healing as potential therapeutic targets	97
Opportunities and challenges in the therapeutic exploitation of histamine and histamine receptor pharmacology in inflammation-driven disorders	95
A novel rationale for targeting FXI: Insights from the hemostatic microRNA targetome for emerging anticoagulant strategies	93
Impact of drug treatment and drug interactions in post-stroke epilepsy	93
CYP2J2-mediated metabolism of arachidonic acid in heart: A review of its kinetics, inhibition and role in heart rhythm control	93
Emerging roles of lysophosphatidic acid receptor subtype 5 (LPAR5) in inflammatory diseases and cancer	88

Organ-on-a-chip platforms as novel advancements for studying heterogeneity, metastasis, and drug efficacy in breast cancer	86
Adenosine receptor signalling as a driver of pulmonary fibrosis	85
Signaling pathways driving ocular malignancies and their targeting by bioactive phytochemicals	84
Editorial Board	83
Exploiting the obesity-associated immune microenvironment for cancer therapeutics	81
Targeting the dysfunction of glutamate receptors for the development of novel antidepressants	81
The role of the STAT3 signaling transduction pathways in radioresistance	79
Targeting adipokines in polycystic ovary syndrome and related metabolic disorders: from experimental insights to clinical studies	79
Current and emerging therapies for Duchenne muscular dystrophy and spinal muscular atrophy	78
Transcription factors in epithelial ovarian cancer: histotype-specific drivers and novel therapeutic targets	78
Pharmaceutical treatment of bone loss: From animal models and drug development to future treatment strategies	77
Myeloperoxidase: A versatile mediator of endothelial dysfunction and therapeutic target during cardiovascular disease	76
Neurobiological mechanisms of botulinum neurotoxin-induced analgesia for neuropathic pain	73
Disease progression modeling with temporal realignment: An emerging approach to deepen knowledge on chronic diseases	73
The unique function of p130Cas in regulating the bone metabolism	72
Chemical inhibitors targeting histone methylation readers	71
Current investigations on clinical pharmacology and therapeutics of Glucose-6-phosphate dehydrogenase deficiency	71
Inflammation, lipids, and pain in vulvar disease	69
Editorial Board	68
Editorial Board	68
Editorial Board	67
Medulloblastoma targeted therapy: From signaling pathways heterogeneity and current treatment dilemma to the recent advances in development of therapeutic strategies	65
Retracing our steps: A review on autism research in children, its limitation and impending pharmacological interventions	65
Behavioral characterization, potential clinical relevance and mechanisms of latent pain sensitization	63
Indirect mediators of systemic health outcomes following nanoparticle inhalation exposure	62
Sodium-glucose co-transporter 2 inhibitors in patients with chronic kidney disease	62
Hedgehog pathway and its inhibitors in chronic obstructive pulmonary disease (COPD)	61
Editorial Board	59
Efficacy and safety of immune-modulating therapy for primary sclerosing cholangitis: A systematic review and meta-analysis	58
Tubulin modifying enzymes as target for the treatment of tau-related diseases	58
The multifaceted functions of RNA helicases in the adaptive cellular response to hypoxia: From mechanisms to therapeutics	57
Naturally occurring mutations in G protein-coupled receptors associated with obesity and type 2 diabetes mellitus	57
Novel treatments for autism spectrum disorder based on genomics and systems biology	57
Resolving inflammation by TAM receptor activation	57
Crosstalk between adenosine receptors and CYP450-derived oxylipins in the modulation of cardiovascular, including coronary reactive hyperemic response	56
Cellular senescence and hematological malignancies: From pathogenesis to therapeutics	55
Novel strategies exploiting interleukin-12 in cancer immunotherapy	55
Modulation of hyaluronan signaling as a therapeutic target in human disease	54
Treatment of chronic cough: P2X3 receptor antagonists and beyond	53
Advances in immunotherapeutic targets for childhood cancers: A focus on glypican-2 and B7-H3	52
Mechanisms and functions of calcium microdomains produced by ORAI channels, d-myo-inositol 1,4,5-trisphosphate receptors, or ryanodine receptors	52
Editorial Board	52
Non-canonical G protein signaling	52
Targeting cancer-associated fibroblasts: Challenges, opportunities and future directions	51
The tissue-specific transcriptional landscape underlines the involvement of endothelial cells in health and disease	50
Matrikines in the skin: Origin, effects, and therapeutic potential	50
Repurposing of pexidartinib for microglia depletion and renewal	49
The mystery of the human proton-organic cation antiporter: One transport protein or many?	49
HIV-associated neurotoxicity and cognitive decline: Therapeutic implications	49
Glucuronidation of orally administered drugs and the value of nanocarriers in strategies for its overcome	48

In cancer, all roads lead to NADPH	48
Ifosfamide - History, efficacy, toxicity and encephalopathy	48
The Triple Crown: NO, CO, and H2S in cancer cell biology	47
Neutrophil extracellular traps: A novel target for the treatment of stroke	47
Targeted treatment of alcoholic liver disease based on inflammatory signalling pathways	46
Vasculogenic mimicry, a complex and devious process favoring tumorigenesis – Interest in making it a therapeutic target	46
Tyrosine kinase and immune checkpoints inhibitors in favorable risk metastatic renal cell carcinoma: Trick or treat?	46
The next frontier in ADME science: Predicting transporter-based drug disposition, tissue concentrations and drug-drug interactions in humans	45
Neurosteroids (allopregnanolone) and alcohol use disorder: From mechanisms to potential pharmacotherapy	45
The IL-18/IL-18R1 signalling axis: Diagnostic and therapeutic potential in hypertension and chronic kidney disease	44
Review: RNA-based diagnostic markers discovery and therapeutic targets development in cancer	44
Toxicology of flavoring- and cannabis-containing e-liquids used in electronic delivery systems	44
Probiotics: Potential novel therapeutics for microbiota-gut-brain axis dysfunction across gender and lifespan	43
Role of inflammatory chemokines in hypertension	43
The complex molecular pharmacology of the dopamine D2 receptor: Implications for pramipexole, ropinirole, and rotigotine	42
The role and participation of immune cells in the endometrial tumor microenvironment	42
Targeting the GBA1 pathway to slow Parkinson disease: Insights into clinical aspects, pathogenic mechanisms and new therapeutic avenues	42
New therapeutic horizons for plasma phospholipid transfer protein (PLTP): Targeting endotoxemia, infection and sepsis	42
Reducing residual cardiovascular risk in Europe: Therapeutic implications of European medicines agency approval of icosapent ethyl/eicosapentaenoic acid	41
Evidence-based strategies for the characterisation of human drug and chemical glucuronidation in vitro and UDP-glucuronosyltransferase reaction phenotyping	40
Functional hydrogels as therapeutic tools for spinal cord injury: New perspectives on immunopharmacological interventions	40
Interplay between fat cells and immune cells in bone: Impact on malignant progression and therapeutic response	40
Endothelial dysfunction as a complication of anti-cancer therapy	40
Oncolytic ImmunoViroTherapy: A long history of crosstalk between viruses and immune system for cancer treatment	39
Inflammation in kidney repair: Mechanism and therapeutic potential	39
The multifaceted landscape behind imatinib resistance in gastrointestinal stromal tumors (GISTs): A lesson from ripretinib	39
Potential neonatal toxicity of new psychoactive substances	39
Targeting ligand-dependent wnt pathway dysregulation in gastrointestinal cancers through porcupine inhibition	38
WITHDRAWN: 17th International conference on bioactive lipids in cancer, inflammation and related diseases virtual special issue	38
Heterogeneity of cGMP signalling in tumour cells and the tumour microenvironment: Challenges and chances for cancer pharmacology and therapeutics	38
Molecular mechanisms of ferroptosis and their involvement in brain diseases	38
Deliver the promise: RNAs as a new class of molecular entities for therapy and vaccination	38
Editorial Board	37
Evidence-based pharmacological treatment options for ADHD in children and adolescents	37
Collateral lethality: A unique type of synthetic lethality in cancers	37
The regulation of PKA signaling in obesity and in the maintenance of metabolic health	37
RET aberrant cancers and RET inhibitor therapies: Current state-of-the-art and future perspectives	36
Recent drug design strategies and identification of key heterocyclic scaffolds for promising anticancer targets	35
The intricate interactions between inflammasomes and bacterial pathogens: Roles, mechanisms, and therapeutic potentials	35
Targeting mGlu5 for Methamphetamine Use Disorder	35
Nitrite and myocardial ischaemia reperfusion injury. Where are we now?	35
The potential therapeutic strategy in combating neurodegenerative diseases: Focusing on natural products	35
Exploring the landscape of post-translational modification in drug discovery	35
Cell-based therapies for vascular regeneration: Past, present and future	35
Organic cation transporters in psychiatric and substance use disorders	35
The pharmacodynamic and pharmacological mechanisms underlying nanovesicles of natural products: Developments and challenges	35
Phosphorylation of nuclear receptors: Novelty and therapeutic implications	35
Multi-omics approaches for biomarker discovery in predicting the response of esophageal cancer to neoadjuvant therapy: A multidimensional perspective	35
Arsenic resistance protein 2 and microRNA biogenesis: Biological implications in cancer development	34
Editorial Board	34
Sulfoconjugation of protein peptides and glycoproteins in physiology and diseases	34
Myeloid cells in the era of cancer immunotherapy: Top 3 unanswered questions	34
Editorial Board	34
Editorial Board	34
Editorial Board	34
Editorial Board	33
Editorial Board	33
Understanding the physiological role of NaV1.9: Challenges and opportunities for pain modulation	33
Cytochrome P450-derived fatty acid epoxides and diols in angiogenesis and stem cell biology	33
Complex in vitro 3D models of digestive system tumors to advance precision medicine and drug testing: Progress, challenges, and trends	33
Targeting the p38α pathway in chronic inflammatory diseases: Could activation, not inhibition, be the appropriate therapeutic strategy?	33
The role of osteoprotegerin (OPG) in fibrosis: its potential as a biomarker and/or biological target for the treatment of fibrotic diseases	32
Comparative efficacy of different treatment modalities in the management of pediatric non-alcoholic fatty liver disease: A systematic review and network meta-analysis	32
Editorial Board	32
Medicinal chemistry, pharmacology, and therapeutic potential of α-conotoxins antagonizing the α9α10 nicotinic acetylcholine receptor	32
RANKL as a key figure in bridging between the bone and immune system: Its physiological functions and potential as a pharmacological target	32
Time is of the essence: Coupling sleep-wake and circadian neurobiology to the antidepressant effects of ketamine	32
Editorial Board	32
The new fate of internalized membrane receptors: Internalized activation	31
Stepping forward in antibody-drug conjugate development	31
Targeting selective autophagy in CNS disorders by small-molecule compounds	31
Secukinumab for the treatment of psoriasis, psoriatic arthritis, and axial spondyloarthritis: Physical and pharmacological properties underlie the observed clinical efficacy and safety	31
UFMylation: An integral post-translational modification for the regulation of proteostasis and cellular functions	30
Programming inflammatory cell death for therapy	30
Kynurenine emerges from the shadows – Current knowledge on its fate and function	30
Bioactive lipids in the skin barrier mediate its functionality in health and disease	30
Branched and linear fatty acid esters of hydroxy fatty acids (FAHFA) relevant to human health	30
The gabapentinoid drugs and their abuse potential	30
Pharmacological modulation of respiratory control: Ampakines as a therapeutic strategy	30
The phospholipase A2 superfamily as a central hub of bioactive lipids and beyond	29

Following the design path of isoform-selective Hsp90 inhibitors: Small differences, great opportunities	29
PPAR-γ signaling in nonalcoholic fatty liver disease: Pathogenesis and therapeutic targets	29
Extracellular vesicles in hepatology: Physiological role, involvement in pathogenesis, and therapeutic opportunities	28
Stem cell therapy in liver regeneration: Focus on mesenchymal stem cells and induced pluripotent stem cells	28
Cancer metastasis: Molecular mechanisms and clinical perspectives	28
Double-edged roles of protein tyrosine phosphatase SHP2 in cancer and its inhibitors in clinical trials	28
Advances in anticancer alkaloid-derived metallo-chemotherapeutic agents in the last decade: Mechanism of action and future prospects	28
Targeting the NLRP3 inflammasome in cardiovascular diseases	28
Targeting post-translational histone modifying enzymes in glioblastoma	27
Non-canonical signaling initiated by hormone-responsive G protein-coupled receptors from subcellular compartments	27
Biased agonism at free-fatty acid receptor-4 (FFA4/GPR120)	27
Aging-related modifications to G protein-coupled receptor signaling diversity	26
Endothelial progenitor cells in the host defense response	26
Dissecting the relationship between antimicrobial peptides and mesenchymal stem cells	26
Endothelial function and dysfunction: Impact of sodium-glucose cotransporter 2 inhibitors	26
Modulating tumor-associated macrophages to enhance the efficacy of immune checkpoint inhibitors: A TAM-pting approach	26
Glyoxalase I is a novel target for the prevention of metabolic derangement	25
The central role of IL-33/IL-1RL1 pathway in asthma: From pathogenesis to intervention	25
Psilocybin for dementia prevention? The potential role of psilocybin to alter mechanisms associated with major depression and neurodegenerative diseases	25
Triggering receptor expressed on myeloid cells-1 (TREM-1) inhibition in atherosclerosis	25
Editorial Board	25
Can N-3 polyunsaturated fatty acids be considered a potential adjuvant therapy for COVID-19-associated cardiovascular complications?	25
Hypertension & dementia: Pathophysiology & potential utility of antihypertensives in reducing disease burden	25
Sleep apnea and pulmonary hypertension: A riddle waiting to be solved	25
Pharmacological data science perspective on fatal incidents of morphine treatment	25
Boron in cancer therapeutics: An overview	25
PARkinson's: From cellular mechanisms to potential therapeutics	24
Preparing to strike: Acute events in signaling by the serpentine receptor for thromboxane A2	24
Review of the application of Kirchhoff's Laws of series and parallel flows to pharmacology: Defining organ clearance	24
Platelet lipid metabolism in vascular thrombo-inflammation	24
Targeting monocytes/macrophages in fibrosis and cancer diseases: Therapeutic approaches	24
Development and clinical translation of P2X7 receptor antagonists: A potential therapeutic target in coronary artery disease?	24
Potassium homeostasis – Physiology and pharmacology in a clinical context	24
Overview of the role of purinergic signaling and insights into its role in cancer therapy	23
Cannabinoids and the endocannabinoid system in fibromyalgia: A review of preclinical and clinical research	23
Purinergic signaling in nervous system health and disease: Focus on pannexin 1	23
Contribution of non-selective membrane channels and receptors in epilepsy	23
New advances in pharmacoresistant epilepsy towards precise management-from prognosis to treatments	23
Nicotine’ actions on energy balance: Friend or foe?	23
Immunomodulation and targeted drug delivery with high intensity focused ultrasound (HIFU): Principles and mechanisms	23
Experimental considerations for the assessment of in vivo and in vitro opioid pharmacology	23
C-type natriuretic peptide (CNP): The cardiovascular system and beyond	23
Macrophage immunometabolism in inflammatory bowel diseases: From pathogenesis to therapy	23
TAAR1 as an emerging target for the treatment of psychiatric disorders	23
Extracellular vesicles in cancer diagnostics and therapeutics	23
Antibody-drug conjugates: Resurgent anticancer agents with multi-targeted therapeutic potential	23
Pulmonary vascular fibrosis in pulmonary hypertension – The role of the extracellular matrix as a therapeutic target	22
Dysregulation of metabolic pathways in pulmonary fibrosis	22
SARS-CoV-2 and other coronaviruses negatively influence mitochondrial quality control: beneficial effects of melatonin	22
Circular RNAs in cardiovascular diseases	22
Dimethyl fumarate induced lymphopenia in multiple sclerosis: A review of the literature	22
The endocrine FGFs axis: A systemic anti-fibrotic response that could prevent pulmonary fibrogenesis?	22
Regulatory lipid vicinal diols counteract the biological activity of epoxy fatty acids and can act as biomarkers and mechanisms for disease progression	22
Potential targeting of the tumor microenvironment to improve cancer virotherapy	22
Is the peroxisome proliferator-activated receptor gamma a putative target for epilepsy treatment? Current evidence and future perspectives	22
Harnessing and delivering microbial metabolites as therapeutics via advanced pharmaceutical approaches	22
Imaging neuroinflammation with TSPO: A new perspective on the cellular sources and subcellular localization	22
Recent advances and future perspectives on carbohydrate-based cancer vaccines and therapeutics	22
The role of sphingosine 1-phosphate metabolism in brain health and disease	22
Novel strategies and promising opportunities for targeted protein degradation: An innovative therapeutic approach to overcome cancer resistance	22
GABAkines – Advances in the discovery, development, and commercialization of positive allosteric modulators of GABAA receptors	22
Pharmacological targets and emerging treatments for respiratory syncytial virus bronchiolitis	22
Prostate Cancer Biomarkers: From diagnosis to prognosis and precision-guided therapeutics	22
Prognostic significance and therapeutic implications of Caveolin-1 in gastrointestinal tract malignancies	22
Novel approaches to target fibroblast mechanotransduction in fibroproliferative diseases	22
The voltage sensitivity of G-protein coupled receptors: Unraveling molecular mechanisms and physiological implications	21
Corrigendum to “Apical sodium-dependent bile acid transporter, drug target for bile acid related diseases and delivery target for prodrugs: Current and future challenges” [Pharmacology & Therapeut	21
Dual inhibition of butyrylcholinesterase and p38α mitogen-activated protein kinase: A new approach for the treatment of Alzheimer's disease	21
TLR4 biased small molecule modulators	21
Short-chain fatty acid receptors and gut microbiota as therapeutic targets in metabolic, immune, and neurological diseases	21
Orthotopic and metastatic tumour models in preclinical cancer research	21
Pathological and pharmacological functions of the metabolites of polyunsaturated fatty acids mediated by cyclooxygenases, lipoxygenases, and cytochrome P450s in cancers	20
The antidepressant actions of ketamine and its enantiomers	20
Vitamin A and retinoid signaling in the kidneys	20
G protein-coupled receptor-effector macromolecular membrane assemblies (GEMMAs)	20
Pharmacological treatment of cardiogenic shock – A state of the art review	20
Metabolic dependencies and targets in ovarian cancer	20
Interactions between NSAIDs, opioids and the gut microbiota - Future perspectives in the management of inflammation and pain	20
The controversial role of beta-blockers in heart failure with preserved ejection fraction	20
Molecular mechanisms and targets of right ventricular fibrosis in pulmonary hypertension	20
The role of FOXP3 in non-small cell lung cancer and its therapeutic potentials	20
Drug-drug interactions that alter the exposure of glucuronidated drugs: Scope, UDP-glucuronosyltransferase (UGT) enzyme selectivity, mechanisms (inhibition and induction), and clinical significance	20
Tumor organoid models in precision medicine and investigating cancer-stromal interactions	20
A review of pre-clinical models for Gulf War Illness	19
A review of pregnancy-induced changes in opioid pharmacokinetics, placental transfer, and fetal exposure: Towards fetomaternal physiologically-based pharmacokinetic modeling to improve the treatment o	19
Bispecific antibodies for the treatment of neuroblastoma	19
Incretin-based drugs as potential therapy for neurodegenerative diseases: current status and perspectives	19
Public health risks associated with chronic, low-level domoic acid exposure: A review of the evidence	19
Therapeutic targets in lung tissue remodelling and fibrosis	18
Molecular mechanisms and cardiovascular implications of cancer therapy-induced senescence	18
Efferocytosis of vascular cells in cardiovascular disease	18
Resolution of inflammation: An organizing principle in biology and medicine	18
Recent advances in studies of SLCO2A1 as a key regulator of the delivery of prostaglandins to their sites of action	18
Emerging role of ferroptosis in breast cancer: New dawn for overcoming tumor progression	18
Wnt signaling: A prospective therapeutic target for chronic pain	18